Russell Investments Group Ltd. lowered its position in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 1.2% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 2,676,163 shares of the company’s stock after selling 32,909 shares during the period. Russell Investments Group Ltd. owned 0.26% of Teva Pharmaceutical Industries Limited worth $88,897,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. Sii Investments Inc. WI boosted its stake in Teva Pharmaceutical Industries Limited by 0.4% in the first quarter. Sii Investments Inc. WI now owns 6,739 shares of the company’s stock worth $214,000 after buying an additional 25 shares in the last quarter. Salem Investment Counselors Inc. boosted its stake in Teva Pharmaceutical Industries Limited by 0.4% in the first quarter. Salem Investment Counselors Inc. now owns 8,332 shares of the company’s stock worth $267,000 after buying an additional 32 shares in the last quarter. Cribstone Capital Management LLC boosted its stake in Teva Pharmaceutical Industries Limited by 3.3% in the first quarter. Cribstone Capital Management LLC now owns 3,141 shares of the company’s stock worth $101,000 after buying an additional 100 shares in the last quarter. Financial Architects Inc boosted its stake in Teva Pharmaceutical Industries Limited by 2.3% in the first quarter. Financial Architects Inc now owns 4,443 shares of the company’s stock worth $143,000 after buying an additional 100 shares in the last quarter. Finally, Sterling Investment Advisors Ltd. boosted its stake in Teva Pharmaceutical Industries Limited by 2.6% in the first quarter. Sterling Investment Advisors Ltd. now owns 3,900 shares of the company’s stock worth $125,000 after buying an additional 100 shares in the last quarter. 56.27% of the stock is currently owned by institutional investors and hedge funds.

Teva Pharmaceutical Industries Limited (NYSE TEVA) opened at 20.60 on Monday. The stock’s 50 day moving average is $32.05 and its 200 day moving average is $32.28. Teva Pharmaceutical Industries Limited has a 12-month low of $20.41 and a 12-month high of $55.45. The stock has a market capitalization of $20.93 billion, a price-to-earnings ratio of 264.10 and a beta of 0.46.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last released its quarterly earnings data on Thursday, August 3rd. The company reported $0.99 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $1.06 by $0.07. The business had revenue of $5.69 billion during the quarter, compared to analysts’ expectations of $5.72 billion. Teva Pharmaceutical Industries Limited had a positive return on equity of 15.96% and a negative net margin of 25.18%. The company’s revenue was up 12.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.25 EPS. Equities research analysts forecast that Teva Pharmaceutical Industries Limited will post $4.44 EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This story was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this story on another website, it was stolen and reposted in violation of international trademark & copyright laws. The legal version of this story can be accessed at https://www.thecerbatgem.com/2017/08/07/teva-pharmaceutical-industries-limited-nyseteva-stake-cut-by-russell-investments-group-ltd-updated.html.

A number of analysts have recently weighed in on TEVA shares. Zacks Investment Research upgraded shares of Teva Pharmaceutical Industries Limited from a “sell” rating to a “hold” rating in a report on Monday, April 17th. Deutsche Bank AG lowered their price target on shares of Teva Pharmaceutical Industries Limited from $45.00 to $43.00 and set a “buy” rating on the stock in a report on Friday, May 12th. Vetr upgraded shares of Teva Pharmaceutical Industries Limited from a “buy” rating to a “strong-buy” rating and set a $37.48 price target on the stock in a report on Tuesday, April 11th. Citigroup Inc. lowered their price target on shares of Teva Pharmaceutical Industries Limited from $47.00 to $42.00 and set a “buy” rating on the stock in a report on Tuesday, April 25th. Finally, Royal Bank Of Canada reiterated an “outperform” rating and issued a $38.00 target price (down from $42.00) on shares of Teva Pharmaceutical Industries Limited in a research note on Monday, May 15th. One analyst has rated the stock with a sell rating, twenty-two have assigned a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus target price of $38.73.

Teva Pharmaceutical Industries Limited Company Profile

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Institutional Ownership by Quarter for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Receive News & Stock Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related stocks with our FREE daily email newsletter.